09.01.2024 • NewsMerck & Co.MSDoncology

Merck & Co. to Acquire Harpoon Therapeutics for $680 Million

US Merck & Co., known as MSD outside of North America, intends to buy cancer drug developer Harpoon Therapeutics for $23.00 per share in cash for an approximate equity value of $680 million.

With this acquisition, MSD bolsters its oncology pipeline as Harpoon has two immunotherapies in early-stage development – one for a type of lung cancer and the other for multiple myeloma.

Harpoon has developed a portfolio of novel T-cell engagers and its lead candidate, HPN328, is currently being evaluated in a Phase 1/2 clinical trial as monotherapy in patients with advanced small cell lung cancer (SCLC) and neuroendocrine tumors. The study is also evaluating HPN328 in combination with atezolizumab in patients with small cell lung cancer (SCLC).

Additional pipeline candidates include HPN217, currently in Phase 1 clinical development for the treatment of patients with relapsed/refractory multiple myeloma, and several preclinical stage candidates, including HPN601, for the treatment of patients with epithelial cell adhesion molecule (EpCAM) expressing tumors.

“With Merck’s recognized leadership in oncology clinical development and global commercial footprint, our lead candidate, HPN328, is well positioned moving forward,” said Julie Eastland, president and CEO of Harpoon Therapeutics. “The talented, passionate and dedicated Harpoon team has made great progress over the past eight years in leveraging our research platform to develop an innovative suite of candidates, and we are pleased that Merck has recognized the significant potential of our pipeline.”

Closing of the acquisition, which has been unanimously approved by Harpoon’s board of directors, is expected in the first half of 2024.

© royaltystockphoto.com/Shutterstock
© royaltystockphoto.com/Shutterstock

CHEManager Spotlight

Standardization and Harmonization of Digital Chemical and Pharmaceutical Logistics
Creating Interfaces

Standardization and Harmonization of Digital Chemical and Pharmaceutical Logistics

CHEManager Spotlight is an exclusive event tailored for practitioners and decision-makers in the chemical industry. This part of our event series delves into the latest trends and innovations in logistics to streamline your operations and drive efficiency.

Interview

Fostering Innovation and Collaboration
Specialty Chemicals Distributor IMCD’s Strategy

Fostering Innovation and Collaboration

Valerie Diele-Braun, CEO of IMCD, shares her vision for sustainability, global expansions, and strategic direction in an exclusive CHEManager International interview.

most read

Photo
24.01.2025 • News

And the Winners are: Cynio, EnaDyne and Green Li-ion

The CHEManager Innovation Pitch, the start-up promotion initiative of CHEManager and CHEManager International, has given more than 100 start-ups from over 15 countries the opportunity to present their innovative ideas, products and technologies to a broad target group since its launch in 2019.

Photo
08.11.2024 • News

Future Prospects in Green Chemistry

The Discourse on Green Chemistry Interactive Pitch Competition, held on November 5, 2024, at Wiley's Berlin office as part of Berlin Science Week, showcased a range of innovative projects aimed at addressing critical environmental challenges.

Photo
27.03.2025 • News

J&J to Invest $55 Billion in US Operations

US healthcare giant Johnson & Johnson (J&J) has unveiled plans to invest over $55 billion in the US over the next four years. This significant investment marks a 25% increase compared to the previous four years, the company said.